Five to eight per cent of HIV-positive individuals initiating abacavir (ABC) experience potentially fatal hypersensitivity reactions (HSRs). We sought to describe the proportion of individuals initiating ABC and to describe the incidence and factors associated with HSR among those prescribed ABC.
Introduction
In the absence of genetic screening, hypersensitivity reaction (HSR) presents in approximately 5-8% of persons living with HIV (PLHIV) initiating abacavir [1, 2] (ABC). HSR can vary in severity and clinical manifestation indicative of multiorgan involvement and includes fever, skin rash, and constitutional, gastrointestinal tract and respiratory symptoms [1] [2] [3] [4] [5] . In rare cases, HSR is fatal [6, 7] . The risk of ABC HSR is high for patients who test positive for the human leucocyte antigen (HLA)-B*5701 allele [1, 8, 9] ; however, ABC HSRs have been reported at a lower frequency in patients who do not carry this allele and therefore risk for HSR can be reduced by HLA-B*5701 screening [1, 3] . ABC should never be initiated in patients with a positive HLA-B*5701 status, and ABC re-challenge among those previously experiencing HSR is contraindicated, as acute onset of potentially fatal symptoms has been reported [2, [10] [11] [12] .
ABC remains a commonly used drug throughout Europe and is recommended as a part of first-line therapy by national and international guidelines [13, 14] ; it is therefore important to continually examine the safety of ABC over time. A previous 2008 report using data from EuroSIDA, a longitudinal cohort collaboration across 35 countries in Europe plus Israel and Argentina [15] , showed an HSR incidence within 3 months of starting ABC of 22.1 [95% confidence interval (CI) 18.7, 25.4] per 100 person-years of follow-up (PYFU) with a decreasing trend for ABC discontinuation because of HSR over time [16] . HSR caused by ABC typically presents within 6 weeks of therapy initiation [4, 17] , and presentation of HSR later than 8 weeks after ABC initiation is almost always attributable to other causes [18] .
The objectives of this study were twofold. First, the aim was to describe the proportion of individuals across Europe on combination antiretroviral therapy (cART) receiving an ABC-based regimen from 1 January 2009 to 1 April 2016 and the factors associated with ABC initiation. Secondly, we sought to describe the cumulative frequency of, incidence of, and factors associated with ABC discontinuation because of reported HSR or because of reported HSR/any toxicity among those starting ABC after 1 January 2009 as part of a cART regimen.
Methods

Study population
EuroSIDA is a longitudinal observational cohort study that was initiated in 1994, and has been previously described [15] . The data collected include start and stop dates for each antiretroviral drug used, reasons for discontinuing an antiretroviral drug and clinical events. Further details on data collected can be found at www.cphiv.dk.
Individuals from the EuroSIDA cohort over the age of 16 years at enrolment receiving cART (at least three drugs from any class, excluding ritonavir) after 1 January 2009 were included in the ABC utilization over time analysis. All persons starting ABC-based cART after 1 January 2009 were eligible for inclusion for analyses of reported HSR-related discontinuation.
Statistical methods
Among those receiving cART and under active follow-up, the proportion of individuals who received ABC at the midpoint of each calendar year (1 July) from 1 January 2009 onwards and by geographical region was summarized using descriptive statistics. Active follow-up was defined as having a first visit date before and last visit date after the midpoint of the year.
Factors associated with ABC utilization were investigated using Poisson regression with generalized estimating equations (GEEs) to control for the inclusion of repeated exposures and events. Baseline was defined as 1 January 2009 or enrolment into EuroSIDA, whichever occurred later. Individuals off ABC contributed follow-up until ABC initiation, the last EuroSIDA visit date or death, whichever occurred first. If an individual stopped ABC they were allowed to re-enter the analysis, and once again were considered eligible for starting ABC. Factors that were significantly associated with ABC initiation (P < 0.1) in univariate analyses were included in multivariable models. Factors investigated were gender, age, ethnicity, HIV transmission risk group, region of care, calendar year, CD4 cell count, nadir CD4 cell count, HIV RNA, line of cART regimen, hepatitis B and C status, previous AIDS diagnosis, Framingham 10-year elevated cardiovascular disease (CVD) risk [19] , chronic kidney disease (CKD), and Data on Adverse Drugs (D:A:D) CKD risk [20, 21] . Line of cART regimen captured the extent of previous antiretroviral treatment and treatment failure and was defined as a change in at least two antiretroviral drugs accompanied by an HIV RNA > 500 HIV-1 RNA copies/mL, or more than 6 months off treatment before starting a new therapy. CKD was defined as two consecutive estimated glomerular filtration rate (eGFR) values < 60 more than 3 months apart using the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula [22] .
For the second objective, analysing reported HSR-related discontinuation, individuals were included if they initiated ABC as part of cART after 1 January 2009. Individuals with prior ABC exposure were included, and individuals who started ABC more than once after 1 January 2009 could contribute multiple exposure periods. Baseline was defined as the start of an ABC-containing regimen, 1 January 2009 or recruitment to EuroSIDA, whichever occurred later. This was an on-treatment analysis where individuals contributed follow-up until 6 weeks after ABC initiation, ABC discontinuation for any cause, death or their last visit date, whichever occurred first. The primary outcome was discontinuation because of reported HSR. We also analysed a composite outcome of discontinuation because of reported HSR or any toxicity, as well as investigating all reasons for discontinuation to account for underreporting and potentially undiagnosed HSR cases.
Factors associated with reported HSR or any toxicityrelated discontinuation were identified in a multivariable Poisson regression model using GEE to adjust for repeated events; those that were significant (P < 0.1) in univariable analyses were included in multivariable models.
Results
Baseline characteristics
Among 10 076 individuals in EuroSIDA receiving cART between 1 January 2009 and 1 April 2016, 3472 (34%; (Fig. 2) . Table 2) .
Discontinuation of ABC
As only 13 persons discontinued because of reported HSR, we could not formally investigate factors associated with reported HSR-related discontinuation. Expanding the endpoint to discontinuation because of reported HSR or any toxicity did not identify any factors associated with discontinuation. The strongest factor associated with discontinuation for reported HSR/any toxicity was nadir CD4 cell count, where those with a nadir CD4 cell count of 350-500 cells/lL were at the highest risk of discontinuing because of reported HSR/any toxicity [IRR 1.60 (95% CI 0.59, 4.37) compared with those with CD4 count < 200 cells/lL; P-heterogeneity = 0.078]. This analysis had limited power as there were few events (n = 35). Seven individuals died within 6 weeks of initiating ABC, all with advanced HIV disease and other comorbidities. HSR was not reported among these individuals and was unlikely to have been the cause of these deaths.
Discussion
Despite the risk of HSR, ABC remains a commonly used antiretroviral drug across Europe in EuroSIDA. Among individuals initiating ABC-based cART after 2009, there were very few discontinuations within 6 weeks of ABC initiation, and discontinuation rates because of reported hypersensitivity reactions were 0.3 (95% CI 0.1, 1.0) per 100 PYFU. There were seven deaths within 6 weeks of starting ABC, but these were likely to have been from causes unrelated to ABC HSR reactions.
ABC utilization was lower among individuals who had been exposed to more treatment regimens and had previous ABC exposure. Because there is evidence to suggest ABC re-challenge should be avoided [5, 12, 23] , it is possible this result is attributable to lower ABC prescription rates among those already exposed to ABC. Unexpectedly, higher ABC utilization was associated with CKD and higher D:A:D CKD risk scores, although this could be attributed to confounding by indication. Use of tenofovir has been linked to kidney disease [24] and individuals on tenofovir with decreasing renal function are likely to discontinue tenofovir [25] and be switched to ABC [26] , a drug with no reported adverse effect on renal function. Changes over time and within regions in use of abacavir probably reflect marketing and availability of abacavir.
Overall, the rate of discontinuation of ABC in the first 6 weeks after starting ABC was low, being similar to the findings of phase II clinical trials [27, 28] , but slightly lower than previous EuroSIDA findings [16] , although the previous EuroSIDA report had a much larger window to observe reported HSR cases (3 months vs. 6 weeks in our study). The rate of stopping because of reported HSR or the composite endpoint of reported HSR or any toxicity was also low, which could indicate the effectiveness of screening for HLA-B*5701, better patient care and a greater understanding of HSR among treating physicians. Screening uptake for the HLA-B*5701 allele has probably avoided many HSR reactions in recent years. EuroSIDA does not collect genetic screening information; thus, it is unknown which individuals were tested for HLA-B*5701, or whether the frequency of testing varied between regions and/or over calendar time.
It is possible that we found low rates of discontinuation as a consequence of using a 6-week window from ABC initiation, but it is well established that this is when HSR is most likely to occur [18] . Even so, compared with early cART, where discontinuation rates at 3 months were reported to be between 10 and 15% [29, 30] , discontinuation because of ABC was low, indicating the effectiveness of screening for HLA-B*5701, improved patient management, improved antiretroviral regimens, reduction in toxicities, and improved adherence [31] . We found no factors significantly associated with ABC discontinuation because of reported HSR/any toxicity, although this might partly be attributable to low power as few patients discontinued.
Along with lack of data on HLA-B*5701 screening, there are other limitations to our study. Most notably, the symptoms of HSR can be difficult to distinguish from other adverse events in the population, possibly leading to over-or underreporting of discontinuation because of reported HSR. EuroSIDA also only collects one reason for discontinuing a drug, so if HSR and another simultaneous reason for discontinuation occurred, HSR may have not been reported as the reason for discontinuation in our data. We have investigated underreporting by using a composite outcome of reported HSR or any toxicity, with consistent results. Finally, the validity of our models depends on the assumption that we appropriately adjusted for confounding; it is, however, possible that our models have residual confounding by indication. Nonetheless, EuroSIDA is in a unique position to compare and describe treatment patterns as a consequence of the standardized nature of the data collection and the inclusion of countries for which there are no national cohorts or surveillance structures.
This study also has several strengths, including the use of a large data set from a heterogeneous population and the inclusion of data from Eastern Europe. In addition, EuroSIDA covers the period 1994-2016 with consistent records of all antiretroviral use and reasons for stopping, allowing comparisons of temporal trends of ABC utilization and subsequent HSR. There has also been consistency in the way data on antiretrovirals and the subsequent reasons for stopping over our study duration have been collected. In summary, ABC remains a commonly used drug throughout Europe, and the incidence of reported HSR among those on ABC is low, probably attributable to screening for HLA-B*5701, improved patient care and a greater understanding and awareness of HSR. Total person-years of follow-up (PYFU) = 778; rate is per 100 PYFU. CI, confidence interval; CNS, central nervous system; GI, gastrointestinal; HSR, hypersensitivity reaction.
